FILING ANALYSIS · WEDNESDAY, OCTOBER 28
Replimune Group, Inc. REPL — 8-K: Results of Operations and Financial Condition
neutral
Replimune's fiscal Q2 results show a net loss of $57.1 million and cash balance of $307.8 million, with TUDRIQEV commercial launch off to a positive start, but the recent capital raise of $141 million in August 2026 may lead to dilution
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →